Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Glutathione peroxidase activity is neuroprotective in models of Huntington's disease.

Mason RP, Casu M, Butler N, Breda C, Campesan S, Clapp J, Green EW, Dhulkhed D, Kyriacou CP, Giorgini F.

Nat Genet. 2013 Oct;45(10):1249-54. doi: 10.1038/ng.2732. Epub 2013 Aug 25.

2.

Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.

Zeng Y, Guo W, Xu G, Wang Q, Feng L, Long S, Liang F, Huang Y, Lu X, Li S, Zhou J, Burgunder JM, Pang J, Pei Z.

Drug Des Devel Ther. 2016 Apr 13;10:1443-51. doi: 10.2147/DDDT.S94666. eCollection 2016.

3.

Synthetic lethal screening in the mammalian central nervous system identifies Gpx6 as a modulator of Huntington's disease.

Shema R, Kulicke R, Cowley GS, Stein R, Root DE, Heiman M.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):268-72. doi: 10.1073/pnas.1417231112. Epub 2014 Dec 22.

4.

Curcumin modulates cell death and is protective in Huntington's disease model.

Chongtham A, Agrawal N.

Sci Rep. 2016 Jan 5;6:18736. doi: 10.1038/srep18736.

5.

Epigenetics of Huntington's disease.

McLauchlan D, Robertson NP.

J Neurol. 2013 Nov;260(11):2938-41. doi: 10.1007/s00415-013-7158-x. No abstract available.

PMID:
24141735
6.

Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease.

van Roon-Mom WM, Pepers BA, 't Hoen PA, Verwijmeren CA, den Dunnen JT, Dorsman JC, van Ommen GB.

BMC Mol Biol. 2008 Oct 9;9:84. doi: 10.1186/1471-2199-9-84.

7.

Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.

Gabery S, Sajjad MU, Hult S, Soylu R, Kirik D, Petersén Å.

Eur J Neurosci. 2012 Sep;36(6):2789-800. doi: 10.1111/j.1460-9568.2012.08193.x. Epub 2012 Jun 25.

PMID:
22731249
8.

A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.

Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ.

Nat Genet. 2005 May;37(5):526-31. Epub 2005 Apr 3.

9.

Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis.

Gipson TA, Neueder A, Wexler NS, Bates GP, Housman D.

RNA Biol. 2013 Nov;10(11):1647-52. doi: 10.4161/rna.26706. Epub 2013 Oct 11.

10.

ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line.

Liang Y, Jiang H, Ratovitski T, Jie C, Nakamura M, Hirschhorn RR, Wang X, Smith WW, Hai T, Poirier MA, Ross CA.

Brain Res. 2009 Aug 25;1286:221-9. doi: 10.1016/j.brainres.2009.06.049. Epub 2009 Jun 24.

11.

Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats.

Colle D, Santos DB, Moreira EL, Hartwig JM, dos Santos AA, Zimmermann LT, Hort MA, Farina M.

PLoS One. 2013 Jun 14;8(6):e67658. doi: 10.1371/journal.pone.0067658. Print 2013.

12.

Therapeutic prospects for the prevention of neurodegeneration in Huntington's disease and the polyglutamine repeat disorders.

Kimura Y, Lee WC, Littleton JT.

Mini Rev Med Chem. 2007 Jan;7(1):99-106. Review.

PMID:
17266642
13.

Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.

Naia L, Ribeiro MJ, Rego AC.

Rev Neurosci. 2011 Dec 2;23(1):13-28. doi: 10.1515/RNS.2011.060. Review.

PMID:
22150069
14.

Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine.

Ribeiro M, Silva AC, Rodrigues J, Naia L, Rego AC.

Toxicol Sci. 2013 Dec;136(2):487-99. doi: 10.1093/toxsci/kft199. Epub 2013 Sep 5.

PMID:
24008831
15.

ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease.

Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, Marsh JL.

Hum Mol Genet. 2011 Jan 15;20(2):261-70. doi: 10.1093/hmg/ddq460. Epub 2010 Oct 15.

16.

MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.

Taylor DM, Moser R, Régulier E, Breuillaud L, Dixon M, Beesen AA, Elliston L, Silva Santos Mde F, Kim J, Jones L, Goldstein DR, Ferrante RJ, Luthi-Carter R.

J Neurosci. 2013 Feb 6;33(6):2313-25. doi: 10.1523/JNEUROSCI.4965-11.2013.

17.

A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.

Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA, Wei SR, Pollio G, Magnoni L, Scali C, Massai L, Franceschini D, Camarri M, Gianfriddo M, Diodato E, Thomas R, Gokce O, Tabrizi SJ, Caricasole A, Landwehrmeyer B, Menalled L, Murphy C, Ramboz S, Luthi-Carter R, Westerberg G, Marsh JL.

Hum Mol Genet. 2014 Jun 1;23(11):2995-3007. doi: 10.1093/hmg/ddu010. Epub 2014 Jan 16.

18.

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.

Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan J, Penney JB, Young AB, Cha JH, Friedlander RM.

Nature. 1999 May 20;399(6733):263-7.

PMID:
10353249
19.

Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.

Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, Webster JA, Lewis TA, O'Kane CJ, Schreiber SL, Rubinsztein DC.

Nat Chem Biol. 2007 Jun;3(6):331-8. Epub 2007 May 7.

20.

Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Dai Y, Dudek NL, Li Q, Fowler SC, Muma NA.

J Neurosci. 2009 Sep 16;29(37):11550-9. doi: 10.1523/JNEUROSCI.3307-09.2009.

Supplemental Content

Support Center